AIDSmeds.com - CROI 2007 : What's New? Update on Experimental Agents

POZ.com | POZ Mentor
POZ Personals

» »

14th Conference on Retroviruses and Opportunistic Infections
Los Angeles, California
February 25-28, 2007

Starting and Switching Treatment | Experimental HIV Drugs
HIV/AIDS Complications and Treatment Side Effects
HIV Transmission and Prevention | Expert Interviews | Diary of a Doc

What's New? Update on Experimental Agents

March 8, 2007

Cal Cohen
AIDSmeds founder Peter Staley interviewed Dr. Calvin Cohen, research director of the Community Research Initiative of New England, about new drugs in the pipeline that might help treatment-experienced patients needing new options. Hear the latest news about Isentress and elvitegravir, two integrase inhibitor, maraviroc, a CCR5 inhibitor, and TMC-278, a new non-nuke.

Double click for the full interview (14 minutes):

Or hear part I about Isentress, Merck's new integrase inhibitor (4 minutes):

Or hear part II about elvitegravir, Gilead's new integrase inhibitor (2 minutes):

Or hear part III about maraviroc, Pfizer's new CCR5 inhibitor (5 minutes):

Or hear part IV about TMC-278, Tibotec's new non-nuke (3 minutes):

Or click here to read the full transcript of the interview.

Our post-CROI conference interviews were generously sponsored by Abbott Laboratories.

Starting and Switching Treatment

March 9, 2007
		Study Finds Viread Advantages in Black Patients

March 6, 2007
		Twice-Daily Kaletra Possibly Better for Some Patients

March 1, 2007
		Once-Daily Viramune Strikes Out

		Fewer Side Effects with Videx/Epivir vs. Combivir

		Still No Clear Benefit of Treating Early HIV (Reuters Health)

February 26, 2007
		One in 10 Infected with Drug-Resistant HIV

Experimental HIV Drugs

March 2, 2007
		Non-Nuke TMC-278 Comparable to Sustiva

March 1, 2007
		Integrase Inhibitor Elvitegravir (GS-9137) Shows Well

February 28, 2007
		Isentress (MK-0518) Results Prove Promising

		Encouraging Data from Two Maraviroc Studies

HIV/AIDS Complications and Treatment Side Effects

March 5, 2007
		Baraclude Induces HIV Drug Resistance

March 2, 2007
		HIV+ Less Responsive to Lipid-Lowering Meds

		Study Says Less Fat for Lower Lipids

February 28, 2007
		Shift in Cancer-Related Deaths in HIV

February 27, 2007
		TH9507 Shows Promise for Lipodystrophy

February 26, 2007
		More Lipoatrophy with Sustiva vs. Kaletra

		Zetia Lowers 'Bad' LDL Cholesterol

		Fosamax, Calcium, and Vitamin D for Bone Weakness

HIV Transmission and Prevention

February 27, 2007
		Breastfeeding Safer for Some HIV+ Mothers (Reuters Health)

Expert Interviews

March 9, 2007
		The Plot Thickens: HIV Treatment Challenges

March 8, 2007
		The Skinny on Metabolic Complications

		What's New? Update on Experimental Agents

Diary of a Doc

March 13, 2007
		Diary of a Doc: On the Origins of HIV

March 2, 2007
		Diary of a Doc: New Strategies for HIV-Herpes Coinfection